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Purpose or Objective: The AIEOP-MH89 protocol aimed to 
optimize treatment results in pediatric Hodgkin lymphoma 
compared to the previous AIEOP-MH83 protocol. Modifications 
included: involved field instead of extended field radiation 
therapy (RT) in early-stage patients (pts); anticipated RT for 
pts with a mass/thorax ratio (M/T)>0.33; enrolment of 
advanced-stage pts in SIOP HD IV protocol. 
 
Material and Methods: Between 1989-1995, 254 evaluable 
pts (median age 10 years, range 2-15 years) received the 
AIEOP-MH89 protocol. The pts were divided into 3 
chemotherapeutic groups according to the clinical stage. 
Group (GR) 1, pts in stages IA and IIA, including those with a 
mass/thorax ratio (M/T)<0.33, received 3 cycles of 
adriamycin, bleomycin, vinblastine, and imidazole 
carboxamide (ABVD). RT was given after completion of 
chemotherapy. GR 2, pts in stages IEA, IB, IA, IIA with 
M/T>0.33, IIB, IIEB, IIIA, IIIS, and IIEA, was treated with 
alternating cycles of nitrogen mustard, vincristine, 
procarbazine, and prednisone (MOPP)/ABVD. The therapeutic 
program included 2 cycles of MOPP/ABVD before radiation 
therapy and 4 cycles MOPP/ABVD after RT. GR 3, pts in 
advanced stages IIIB, IVA and IVB, was treated according to 
the SIOP HD IV-87 protocol, with 2 cycles of vincristine, 
procarbazine, prednisone, adriamycin, (OPPA) and 2 cycles of 
cyclophosphamide vincristine, procarbazine, prednisone 
(COPP) followed by RT. Pts enrolled in GR 1 and 3 were 
treated with involved field RT. Pts with positive cervical 
lymph nodes received RT to the neck. In positive axillary 
lymph nodes, RT included also the sovraclavear region. Pts 
with mediastinal disease were treated with mediastinum and 
bilateral supraclavicular fossa RT, whereas pts with 
involvement of both mediastinum and other supra 
diaphragmatic lymph nodes stations received the 
conventional mantle RT. Pts with positive single inguinal 
lymph node received also comprensive RT to omolateral iliac 
nodal stations, whereas in case of multiple subdiaphragmatic 
lymph nodes disease, bilateral iliac nodal stations irradiation 
was avoided if not directly involved. The radiation doses 
were established according to response to initial 
chemotherapy, and were the same in GR 1 and 2: pts in CR 
and ≥75% PR received 20 Gy, whereas <75% PR received 40 
Gy. GR 3 pts with CR or ≥75% PR received 20 Gy, and 36 Gy 
those with 75% PR. 
 
Results: In table 1 are reported the results in term of Overall 
Survival (OS) and Event Free Survival (EFS). Long term side 
effects of treatment were evaluated (median follow-up 
duration 16 years): 25.6% of the pts developed thyroid 
complications and 6.6% secondary malignancies. 
 
 
 
Conclusion: The AIEOP-MH89 protocol improves globally OS 
and EFS. In GR 1 OS and EFS are the same compared to the 
previous protocol, minimizing radiation exposure. In GR 2 and 
3 OS and EFS improved because of therapeutic changes. 
Analysis of delayed toxicities underlines the importance of 
long-term monitoring of pts. 
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Purpose or Objective: Childhood cancer survivors (CCS) face 
high risk for late effects. Aside from malignant neoplasms, it 
is known that ionizing radiation induces benign tumours of, 
e.g., the central nervous system and other sites. Record-
linkage with pathology report registries provides a unique 
opportunity to obtain non-selected and uniformly collected 
benign tumour information. We aim to estimate the 
incidence of histologically-confirmed solid benign tumours 
(SBT), to describe clinical characteristics and to quantify the 
role of radiotherapy (RT). 
 
Material and Methods: The Dutch Childhood Oncology Group 
– Late effects after childhood cancer (DCOG LATER) is a 
collaborative effort of all 7 academic paediatric 
hemato/oncology centres in the Netherlands with clinicians 
and researchers who focus on optimal patient care and 
research in CCS. The DCOG LATER cohort includes 6168 five-
yr CCS treated between 1963 and 2001 before the age of 18 
yrs. The entire DCOG LATER cohort was linked with the 
nationwide Dutch Pathology Registry (PALGA) to ascertain 
histologically confirmed SBT (excluding skin) diagnosed 
between 1990-2014. 
 
Results: We identified 1278 eligible pathology reports in 788 
CCS after a median follow up since diagnosis of 22 yrs (max. 
52). We excluded reports on SBT diagnosed within 5 yrs after 
childhood cancer (243 reports); 145 reports without a clear 
diagnosis in conclusion and 25 reports still to be classified. 
These preliminary analyses include 865 reports from 578 CCS, 
of whom 79% had one SBT, and 21% had multiple. Tumour 
locations included head/neck/CNS (36%), chest (13%), 
abdomino-pelvic (34%), and extremities (14%). Of 3% location 
was unclear. Most common SBT types in the head/neck/CNS 
were meningiomas (44%), often following cranial 
radiotherapy (RT) (95%); mammary fibroadenomas (49%), 1 in 
6 after RT chest; colorectal adenoma (38%), including 1 in 4 
after abdominopelvic RT, and female genital tract tumours 
(leiomyomas and ovarian mucinous cystadenomas) (29%), 1 in 
3 after abdominopelvic RT. We will present effects of RT 
dose, chemotherapy and genetic syndromes. 
 
Conclusion: This preliminary analyses give insight into the 
amount and types of histologically confirmed SBT in CCS in 
relation to RT. To our knowledge, this is one of the first 
comprehensive assessments of subsequent SBT among CCS. In 
ongoing clinical follow-up studies we aim to gain knowledge 
about risk factors and clinical characteristics (e.g. 
meningioma) to help guideline groups decide for or against 
screening of asymptomatic, high-risk CCS. 
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Purpose or Objective: Feasibility study for the clinical 
implementation of a hybrid radiation therapy system 
consisting of an MR-on-rails scanner and a linear accelerator. 
 
Material and Methods: A 1.5 T MR-on-rails system (IMRIS, 
Minnetonka, MN) was configured a) to be used as a 
standalone MR simulator in a dedicated suite or b) to travel 
on ceiling-mounted rails to an adjacent linac vault and 
operate in the vicinity of a 6X FF/FFF TrueBeam therapy 
system (Varian Medical System, Palo Alto, CA). The in-room 
MR guidance is intended be used in conjunction with the 
standard linac’s kV imaging for the patient setup verification 
and treatment delivery. Key aspects of the MR and linac 
integration were investigated such as: magnetic field 
coupling of the MR with the linac vault environment, RF 
noise, RT workflows, safety systems, and QC procedures. 
Numerical simulations and measurements were performed to 
establish the magnetic field optimal separation between the 
MR and linac. A FEM-based simulation space was built and 
validated to mimic the full-scale MR-linac/couch system; this 
provided a detailed picture of the magnetic field coupling 
effects and guided the engineering activities. Field mapping 
was performed with low/high field Hall probes, and pull 
forces on couch sub-components were measured via a force 
gauge for several scenarios. Hysteresis effects on the linac 
beam performance were quantified by measuring the 
flatness/symmetry/output vs. gantry angle for short and 
long-term MR’s field exposures. The MR performance was 
evaluated using procedures available in the service mode of 
the MR console as well as dedicated methods developed in-
house (e.g. B0 mapping). RF noise isolation was achieved by 
parking the linac behind specially designed RF doors during 
the MR imaging sessions. An interlocking system was designed 
and implemented to enforce the safe linac curation (e.g. 
gantry position, doors statues and table position) prior to 
MR’s travel into the vault. 
 
